Skip to main content
Premium Trial:

Request an Annual Quote

Detroit R&D Awarded $1M Phase II SBIR Grant

NEW YORK (GenomeWeb News) – Detroit R&D today announced it has been granted a two-year $1 million Small Business Innovation Research Phase II grant to continue research into protein glycosylation.

The grant from the National Cancer Institute will be used by the company to continue work carried out with a Phase I SBIR grant in 2012 for $300,000, it said. In the Phase I study, Detroit R&D developed glycosylation site-specific antibodies for oncogene proteins and cancer-suppressor proteins, as well as methods for screening anti-cancer drugs. The company developed a microarray-based method for screening glycosylated protein biomarkers in prostate cancer.

With the new funding, the company plans to produce approximately 40 site-specific antibodies for glycosylated receptors and signal transduction pathway proteins. Detroit R&D also plans to elucidate the functions of protein glycosylation in cancer, it said.

The research is anticipated to lead to the development of diagnostics and therapeutics directed at breast, prostate, and pancreatic cancers.

The Phase II study lasts until September 2015.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.